Artery stapling technology attracts investors to AngioLink:
This article was originally published in Clinica
Executive Summary
AngioLink, a Taunton, Massachusetts company, has raised $13.6m from a preferred equity offering. The funds will help it prepare for the market launch of stapling technology it has developed to close femoral arteries after catheterisation procedures. The EVS vascular closure system, which could also be used for other surgical applications, is nearing completion of clinical trials in the US, the company says. The vascular sealing market is estimated at $300m and could grow to $2bn, according to the company.